Inspection Record

Hikma Injectables USA Inc. — FDA 483 Findings

US FDAInspected 2024-06-25Published 2024-07-26 4 findingsLaboratory and QC controlsAseptic processing and sterility assurance

Inspectors Edmund F Mrak · Ogechi C Nna · Luxuly AbrahamThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Samples taken of drug products for determination of conformance to written specifications are not representative.

2Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

3Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

4Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

About this record

Extracted automatically from the document US FDA published on 2024-07-26. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Hikma Injectables USA Inc. findings history — including this company's other documents US FDA documents, 2024 Go to Findings search